X4 Pharmaceuticals Q3 2026 Earnings Date & Estimates

X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency that can cause chronic neutropenia, lymphopenia and recurrent infections. XOLREMDI is designed to increase the number of circulating neutrophils and lymphocytes, potentially helping reduce infection-related complications.

Founded in 2014 and headquartered in Boston, Massachusetts, X4 Pharmaceuticals has historically focused on rare immunological and hematological disorders with significant unmet medical needs. In addition to its commercial efforts for XOLREMDI in the United States, the company has evaluated mavorixafor in other forms of chronic neutropenia and related conditions. X4 Pharmaceuticals trades on the Nasdaq under the symbol XFOR.